Similarly, anti-IL-6 and anti-IL-6R antibodies, such as Sarilumab, Siltuximab and Tocilizumab have been tested for their ability to control virus-induced hyper-inflammation in COVID-19 patients (61–63). This evidence concerns the gene IL6R and COVID-19.